Lotus Pharmaceutical Overview

  • Year Founded
  • 1966

Year Founded

  • Status
  • Public

  • Employees
  • 94

Employees

  • Stock Symbol
  • 1795

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $3.07
  • (As of Friday Closing)

Lotus Pharmaceutical General Information

Description

Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. Along with its subsidiaries, it is engaged in the research and development, manufacturing, and sales of generic and branded pharmaceutical products, as well as consulting services. Its product portfolio comprises biosimilars, generic medicines, branded medicines, and various therapies in its research and development pipeline. The Group offers a differentiated portfolio of pharmaceuticals spanning several therapeutic areas, including oncology and immunology, CNS, women's health, primary care and lifestyle, and nephrology, among others. Geographically, it generates maximum revenue from the United States, and the rest from Taiwan, South Korea, Singapore, and other countries.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 17th Floor, Number 277
  • Song Ren Road, Xin Yi District
  • Taipei City, 110
  • Taiwan
+886 02
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
TAI
Corporate Office
  • 17th Floor, Number 277
  • Song Ren Road, Xin Yi District
  • Taipei City, 110
  • Taiwan
+886 02

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Lotus Pharmaceutical Stock Performance

As of 20-Nov-2026, Lotus Pharmaceutical’s stock price is $3.07. Its current market cap is $818M with 266M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.07 $3.38 $3.04 - $11.54 $818M 266M 1.26M $0.27

Lotus Pharmaceutical Financials Summary

As of 30-Sep-2026, Lotus Pharmaceutical has a trailing 12-month revenue of $984M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 3,128,654 2,594,397 2,438,152 2,635,693
Revenue 984,142 657,444 579,118 544,431
EBITDA 295,881 257,527 252,790 219,577
Net Income 70,394 151,304 157,851 131,810
Total Assets 3,485,855 3,394,362 1,219,473 1,073,665
Total Debt 1,577,462 1,518,083 415,597 377,011
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Lotus Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Lotus Pharmaceutical‘s full profile, request access.

Request a free trial

Lotus Pharmaceutical Patents

Lotus Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4374853-A1 Solid formulation of enzalutamide Inactive 22-Nov-2022
EP-4302755-A1 Palbociclib formulation containing an amino acid Active 07-Jul-2022
EP-4302755-B1 Palbociclib formulation containing an amino acid Active 07-Jul-2022
EP-4302832-A1 Palbociclib formulation containing glucono delta lactone Inactive 07-Jul-2022
EP-4260848-A1 Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation Inactive 11-Apr-2022 A61K9/2009
To view Lotus Pharmaceutical’s complete patent history, request access »

Lotus Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Lotus Pharmaceutical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Lotus Pharmaceutical‘s full profile, request access.

Request a free trial

Lotus Pharmaceutical Investments & Acquisitions (7)

Lotus Pharmaceutical’s most recent deal was a Merger/Acquisition with Sandoz Philippines for . The deal was made on 02-Apr-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sandoz Philippines 02-Apr-2026 Merger/Acquisition Distributors (Healthcare)
Alvogen Group 03-Dec-2025 Merger/Acquisition Drug Discovery
Duy Tan Pharmaceutical (Five Pharmaceutical Products in Vietnam) 30-Sep-2025 Corporate Asset Purchase Buildings and Property
Sanofi (Alphachymotrypsine Choay Business in Vietnam and Cambodia) 07-Jan-2025 Merger/Acquisition Pharmaceuticals
Teva Pharma (Thailand) Company 06-Jun-2024 Merger/Acquisition Other Healthcare Services
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Lotus Pharmaceutical ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

26.07 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Lotus Pharmaceutical’s complete esg history, request access »

Lotus Pharmaceutical Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Alvogen Group Morristown, NJ 2007

Lotus Pharmaceutical FAQs

  • When was Lotus Pharmaceutical founded?

    Lotus Pharmaceutical was founded in 1966.

  • Where is Lotus Pharmaceutical headquartered?

    Lotus Pharmaceutical is headquartered in Taipei City, Taiwan.

  • What is the size of Lotus Pharmaceutical?

    Lotus Pharmaceutical has 94 total employees.

  • What industry is Lotus Pharmaceutical in?

    Lotus Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Lotus Pharmaceutical a private or public company?

    Lotus Pharmaceutical is a Public company.

  • What is Lotus Pharmaceutical’s stock symbol?

    The ticker symbol for Lotus Pharmaceutical is 1795.

  • What is the current stock price of Lotus Pharmaceutical?

    As of 20-Nov-2026 the stock price of Lotus Pharmaceutical is $3.07.

  • What is the current market cap of Lotus Pharmaceutical?

    The current market capitalization of Lotus Pharmaceutical is $818M.

  • What is Lotus Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Lotus Pharmaceutical is $984M.

  • What is Lotus Pharmaceutical’s annual earnings per share (EPS)?

    Lotus Pharmaceutical’s EPS for 12 months was $0.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process